Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17413988rdf:typepubmed:Citationlld:pubmed
pubmed-article:17413988lifeskim:mentionsumls-concept:C0375071lld:lifeskim
pubmed-article:17413988lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:17413988lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:17413988lifeskim:mentionsumls-concept:C0677055lld:lifeskim
pubmed-article:17413988lifeskim:mentionsumls-concept:C1514475lld:lifeskim
pubmed-article:17413988lifeskim:mentionsumls-concept:C0487602lld:lifeskim
pubmed-article:17413988lifeskim:mentionsumls-concept:C1441616lld:lifeskim
pubmed-article:17413988lifeskim:mentionsumls-concept:C1519522lld:lifeskim
pubmed-article:17413988pubmed:issue2lld:pubmed
pubmed-article:17413988pubmed:dateCreated2007-4-6lld:pubmed
pubmed-article:17413988pubmed:abstractTextThe aim of this study is to determine immunohistochemical markers with prognostic significance for disease-specific survival in patients with squamous cell cancer of the vulva. The study material consisted of slides and paraffin blocks of 50 vulvectomy specimens. A tissue microarray was constructed and stained with 16 antibodies. The impact of lymph node metastases, size of tumor, vascular space involvement, and the marker expression on disease-specific survival was calculated. In univariate analysis lymph node metastases, tumor size more than 4 cm, vascular space involvement, strong cyclooxygenase 2 expression, and absent Caspase 3 expression were significantly associated with disease-specific survival. In a multivariate analysis, poor disease-specific survival is independently associated with absent Caspase 3 expression (hazard ratio, 0.2; 95% confidence interval, 0.04-0.97; P = 0.045). Five-year survival was 86% in patients with tumors positive for Caspase 3 (n = 20) and drops to 64% in patients with Caspase 3-negative tumors (n = 30). In this test set, cyclooxygenase 2 and Caspase 3 seem to be immunohistochemical markers with prognostic significance for vulva cancer. The results have to be validated.lld:pubmed
pubmed-article:17413988pubmed:languageenglld:pubmed
pubmed-article:17413988pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17413988pubmed:citationSubsetIMlld:pubmed
pubmed-article:17413988pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17413988pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17413988pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17413988pubmed:statusMEDLINElld:pubmed
pubmed-article:17413988pubmed:monthAprlld:pubmed
pubmed-article:17413988pubmed:issn0277-1691lld:pubmed
pubmed-article:17413988pubmed:authorpubmed-author:van der...lld:pubmed
pubmed-article:17413988pubmed:authorpubmed-author:FonsGuusGlld:pubmed
pubmed-article:17413988pubmed:authorpubmed-author:Ten...lld:pubmed
pubmed-article:17413988pubmed:authorpubmed-author:BurgerMatthe...lld:pubmed
pubmed-article:17413988pubmed:issnTypePrintlld:pubmed
pubmed-article:17413988pubmed:volume26lld:pubmed
pubmed-article:17413988pubmed:ownerNLMlld:pubmed
pubmed-article:17413988pubmed:authorsCompleteYlld:pubmed
pubmed-article:17413988pubmed:pagination188-93lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:meshHeadingpubmed-meshheading:17413988...lld:pubmed
pubmed-article:17413988pubmed:year2007lld:pubmed
pubmed-article:17413988pubmed:articleTitleIdentification of potential prognostic markers for vulvar cancer using immunohistochemical staining of tissue microarrays.lld:pubmed
pubmed-article:17413988pubmed:affiliationDepartment of Obstetrics and Gynecology, Academic Medical Center, Amsterdam, Netherlands. g.fons@amc.uva.nllld:pubmed
pubmed-article:17413988pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:836entrezgene:pubmedpubmed-article:17413988lld:entrezgene
entrez-gene:5743entrezgene:pubmedpubmed-article:17413988lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17413988lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17413988lld:entrezgene
lhgdn:association:4412lhgdn:found_inpubmed-article:17413988lld:lhgdn
lhgdn:association:30132lhgdn:found_inpubmed-article:17413988lld:lhgdn